Uric acid therapy improves the outcomes of stroke patients treated with intravenous tissue plasminogen activator and mechanical thrombectomy

• Published in: International journal of stroke 2017-06, Vol.12 (4), p.377-382
• Main Authors: Chamorro, Ángel, Amaro, Sergio, Castellanos, Mar, Gomis, Meritxell, Urra, Xabier, Blasco, Jordi, Arenillas, Juan F, Román, Luis S, Muñoz, Roberto, Macho, Juan, Cánovas, David, Marti-Fabregas, Joan, Leira, Enrique C, Planas, Anna M
• Format: Article
• Language: English
• Subjects: Aged, 80 and over; Brain Ischemia - therapy; Female; Fibrinolytic Agents - therapeutic use; Humans; Male; Middle Aged; Stroke - therapy; Thrombectomy - methods; Tissue Plasminogen Activator - therapeutic use; Treatment Outcome; Uric Acid - therapeutic use
• ISSN: 1747-4930; 1747-4949
• DOI: 10.1177/1747493016684354

Background Numerous neuroprotective drugs have failed to show benefit in the treatment of acute ischemic stroke, making the search for new treatments imperative. Uric acid is an endogenous antioxidant making it a drug candidate to improve stroke outcomes. Aim To report the effects of uric acid therapy in stroke patients receiving intravenous thrombolysis and mechanical thrombectomy. Methods Forty-five patients with proximal vessel occlusions enrolled in the URICO-ICTUS trial received intravenous recombinant tissue plasminogen activator within 4.5 h after stroke onset and randomized to intravenous 1000 mg uric acid or placebo (NCT00860366). These patients also received mechanical thrombectomy because a brain computed tomogaphy angiography confirmed the lack of proximal recanalization at the end of systemic thrombolysis. The primary outcome was good functional outcome at 90 days (modified Rankin Score 0–2). Safety outcomes included mortality, symptomatic intracerebral bleeding, and gout attacks. Results The rate of successful revascularization was >80% in the uric acid and the placebo groups but good functional outcome was observed in 16 out of 24 (67%) patients treated with uric acid and 10 out of 21 (48%) treated with placebo (adjusted Odds Ratio, 6.12 (95% CI 1.08–34.56)). Mortality was observed in two out of 24 (8.3%) patients treated with uric acid and one out of 21 (4.8%) treated with placebo (adjusted Odds Ratio, 3.74 (95% CI 0.06–226.29)). Symptomatic cerebral bleeding and gout attacks were similar in both groups. Conclusions Uric acid therapy was safe and improved stroke outcomes in stroke patients receiving intravenous thrombolysis followed by thrombectomy. Validation of this simple strategy in a larger trial is urgent.